Ocular Drug Delivery Articles

  1. Pharmaceutical Nanotechnology: What To Know 8/10/2022

    Here is what you need to know about the key advantages that pharmaceutical nanotechnology provides in improving drug efficacy and decreasing adverse reactions.

  2. Drug Formulation Development: Quick Reference Guide 7/11/2022

    This guide shares the steps involved in formulation development, considerations during formulation, and how partnering with an experienced CDMO can lead to a successful commercial product.

  3. Ocular + Auditory Cell Therapies: Lineage Cell Therapeutics 2.0 4/25/2022

    On the heels of a lucrative deal with Roche/Genentech for its Phase I/IIa dry age-related macular degeneration candidate, Lineage Cell Therapeutics is fording new waters with a promising auditory neuropathy spectrum disorder candidate. CEO Brian Culley shares the strategy.

  4. Opus Genetics, Resilience Partner On Ocular Gene Therapy 4/13/2022

    Opus Genetics has partnered with Resilience for the development and manufacturing of AAV-based gene therapies for inherited retinal diseases. Opus’ first two programs in LCA target the LCA-5 and RDH12 genes and are licensed from the University of Pennsylvania and based on the work of Opus scientific cofounder, Jean Bennett, M.D., Ph.D., the F.M. Kirby Emeritus Professor of Ophthalmology at the Perelman School of Medicine. Opus’ third program is licensed from Massachusetts Eye and Ear / Harvard and is designed to address NMNAT1-associated retinal degeneration.

  5. Small Is Powerful And Sustained

    Advances in sustained-release drug delivery could improve efficiency and consistency in drug release, manifesting real-life advantages for patients in the form of enhanced accessibility and compliance.

  6. Four Challenges That Stall Advanced Therapy Development

    Many challenges can stall an advanced therapy’s development. The vast majority of them are tied to inadequate preclinical planning and partner vetting.